-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3487 The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Program: Oral and Poster Abstracts
Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster II
Hematology Disease Topics & Pathways:
multiple myeloma, Diseases, Plasma Cell Disorders, Lymphoid Malignancies, Quality Improvement
Sunday, December 8, 2019, 6:00 PM-8:00 PM
Hall B, Level 2 (Orange County Convention Center)

Paul G. Richardson, MD1, Alessandra Larocca2, Xavier Leleu, MD, PhD3, Albert Oriol, MD4*, Agne Paner, MD5, Paula Rodriguez Otero6*, Cyrille Touzeau, MD7*, Adrián Alegre Amor, MD8*, Christopher Maisel, MD9, María-Victoria Mateos, MD, PhD10, Amitabha Mazumder, MD11*, Peter Strang, MD12*, Oskar Öhman, MSc13*, Johan Harmenberg, MD, PhD13*, Stojan Zavisic13* and Joan Bladé, MD14*

1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2A.O.U. Città della Salute e della Scienza di Torino - S.C. Ematologia U, Torino, Italy
3CHU de Poitiers, Poitiers, France
4Hospital Germans Trias i Pujol, Badalona, Spain
5Rush University Medical Center, Bolingbrook, IL
6Clínica Universidad de Navarra, Pamplona, Spain
7Department of Hematology, Nantes University Hospital, Nantes, France
8Hospital Universitario La Princesa, Madrid, Spain
9Baylor Scott & White Charles A Sammons Cancer Center, Dallas, TX
10Hospital Clinico Universitario de Salamanca, Salamanca, Spain
11The Oncology Institute of Hope and Innovation, Glendale, CA
12Karolinska Institutet, Stockholm, Sweden
13Oncopeptides AB, Stockholm, Sweden
14Hospital Clínica de Barcelona - Servicio de Onco-Hematología, Barcelona, Spain

Background: Due to advances in therapy, outcomes have improved in multiple myeloma (MM). However, the improvement in overall survival (OS) is associated with a greater proportion of patients living with the burden of symptoms and complications of relapsed/refractory MM (RRMM) and prior lines of therapy (Vogl et al. Leuk Lymphoma. 2009). There are limited treatment options for late-stage RRMM refractory to pomalidomide (pom) and/or daratumumab (dara). Treatment goals for these late-stage patients should include extending OS but also preserving health-related quality of life (HRQOL) and managing disease-related symptoms (Jordan et al. Support Care Cancer. 2014).

Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytotoxic payload into myeloma cells through peptidase activity. Melflufen is taken up by myeloma cells and immediately cleaved by peptidases into hydrophilic alkylator payloads that induce irreversible DNA damage and apoptosis. In phase 2 HORIZON, melflufen + dexamethasone (dex) has demonstrated encouraging efficacy in patients with RRMM refractory to dara and/or pom (overall response rate [ORR], 30%; median progression-free survival, 4 months; median OS, 10 months) and was well tolerated, with infrequent nonhematologic adverse events (AEs) and low rates of discontinuation due to AEs (Richardson et al. EHA 2019; Abstract S1605). This analysis examines baseline HRQOL in the HORIZON study as well as other published studies in RRMM and other advanced cancers, to help characterize the burden of relapsed/refractory disease.

Methods: In HORIZON, patients with RRMM must have received ≥2 prior lines, been exposed to an IMiD and PI, and be refractory to pom and/or dara. HRQOL, a secondary endpoint, was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and the EuroQol 5 Dimension-3 Level (EQ-5D-3L) questionnaire. Questionnaires were administered at baseline and at intervals, through study completion. A literature search was conducted to identify other studies of baseline HRQOL in comparable patient populations with RRMM and other advanced cancers.

Results: As of data cutoff (20 June 2019), 41 patients on HORIZON had baseline HRQOL data: median age, 66 y (46-84); median time since diagnosis, 5.7 y (2-17), 22% International Staging System stage 3 disease, 74% (n=27 evaluable) high-risk cytogenetics at study entry. Additionally, 6 studies with baseline EORTC QLQ-C30 HRQOL data, representing 2068 patients with RRMM with at least 2 prior lines, were identified in the literature, including 2 analyses of dara expanded access programs (EAPs) and the ASPIRE and PANORAMA phase 3 clinical trials (Figure). In HORIZON, QLQ-C30 baseline Global Health Status score was 57.1 (scale 0-100). This was relatively comparable to other RRMM studies (range, 54.8-58.6). QLQ-C30 Functional Domain and Symptom Domain scores were also comparable across HORIZON and other RRMM studies. In HORIZON, EQ-5D baseline mean utility score was 0.74 (scale 0-1) and baseline health state visual analog score (VAS) was 60.54 (scale 0-100). These were similar to EQ-5D baseline mean utility scores of 0.75 and 0.66 and VAS of 63.06 and 57.59 reported in the US and EU + Russia dara EAP analyses, respectively, indicating similar baseline HRQOL across these populations.

To contextualize the disease burden in RRMM, reports of HRQOL in other advanced cancers were identified in the literature. In a study of 534 patients with advanced cancer of the bladder, brain, breast, colon/rectum, head/neck, hepatobiliary tract/pancreas, kidney, lung, lymphoma, ovary, or prostate, EQ-5D mean utility scores ranged from 0.74-0.83 and mean VAS ranged from 61.8-72.0 (Pickard et al. Clin Ther. 2016). Despite limitations of cross-study comparisons, this suggests patients with RRMM have a similar, or potentially higher, disease burden as those with other advanced cancers.

Conclusion: Despite differences in patient populations and prior lines of therapy across published studies, patients with RRMM and ≥2 prior therapies had remarkably similar HRQOL. Baseline HRQOL data from HORIZON confirm these patients are representative of the disease burden of other RRMM populations described in the literature. Overall, this comparison indicates that RRMM represents a high burden of disease among patients with advanced cancers.

Disclosures: Richardson: Amgen: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Sanofi: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol-Myers Squibb: Research Funding. Larocca: Amgen: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Leleu: Merck: Honoraria; Sanofi: Honoraria; Novartis: Honoraria; Incyte: Honoraria; Carsgen: Honoraria; Amgen: Honoraria; Karyopharm: Honoraria; Takeda: Honoraria; Oncopeptide: Honoraria; BMS: Honoraria; Janssen: Honoraria; Celgene: Honoraria; GSK: Honoraria; AbbVie: Honoraria. Oriol: Janssen: Consultancy; Amgen: Consultancy, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Celgene Corporation: Consultancy, Speakers Bureau. Paner: Amgen: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Cellectar: Consultancy, Honoraria; Rush University Medical Center: Employment; Dova: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria. Rodriguez Otero: Takeda: Consultancy; BMS: Honoraria; Kite Pharma: Consultancy; Celgene Corporation: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria. Amor: Celgene: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees. Maisel: Gilead: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; Incyte: Honoraria, Speakers Bureau; Takeda: Honoraria, Speakers Bureau; Celgene: Honoraria, Speakers Bureau; Amgen: Honoraria, Speakers Bureau; Texas Oncology: Employment; Verastem: Honoraria, Speakers Bureau. Mateos: Abbvie: Membership on an entity's Board of Directors or advisory committees; Pharmamar: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; EDO: Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; Adaptive: Honoraria; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Strang: Karolinska Institutet: Employment; Oncopeptides: Consultancy; Stockholm Sjukhem Foundation: Research Funding. Öhman: Oncopeptides: Employment, Equity Ownership. Harmenberg: Oncopeptides: Consultancy, Equity Ownership. Zavisic: Oncopeptides AB: Employment, Equity Ownership. Bladé: Jansen, Celgene, Takeda, Amgen and Oncopeptides: Honoraria.

OffLabel Disclosure: This is a phase 2 investigational study of melflufen in RRMM

*signifies non-member of ASH